Rocephin is a Small Molecule owned by F. Hoffmann-La Roche, and is involved in 2 clinical trials, which were completed.

Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It binds to Penicillin-Binding Proteins (PBPs) located inside the bacterial cell wall and inhibits the third and last transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.

The revenue for Rocephin is expected to reach a total of $2.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rocephin NPV Report.

Rocephin is currently owned by F. Hoffmann-La Roche.

Rocephin Overview

Ceftriaxone sodium (Rocephin, Rocefin) is a semi-synthetic, broad-spectrum third generation cephalosporin antibiotic resistant to beta-lactamase. It is formulated as injection powder for solution for intravenous or intramuscular route of administration. Rocephin, Rocefin is indicated for the treatment of several types of bacterial infections such as lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, urinary tract infections, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, community acquired pneumonia, hospital acquired pneumonia, intra-abdominal infections, meningitis, surgical prophylaxis and skin and soft tissue infections.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Rocephin

Report Segments
  • Innovator (NME)
Drug Name
  • Rocephin
Administration Pathway
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Ear Nose Throat Disorders
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
  • Musculoskeletal Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.